BLU-001 Blue Peel RADIANCE™ - Obagi Medical Products...Suzanne Bruce, MD 2 BLU-001 Blue Peel...

Preview:

Citation preview

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

BLU-001 Blue Peel RADIANCE™

FINAL ANALYSIS

December 2012 JoAnne Watson, D.P.M., Associate Director, Clinical Affairs

Barbara Coffey, Project Coordinator

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

A Single-Center Five-Week Open Label Study to Evaluate the

Efficacy of a Series of Three Peel Procedures using Obagi

Blue Peel RADIANCE ™ in the Improvement of the

Appearance of Facial Skin

INVESTIGATOR:

Suzanne Bruce, MD

2 2

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

Subjects (male and female) at one site in a 5 week study to

evaluate the efficacy and improvement in the appearance of the

facial skin after using the Obagi® Blue Peel RADIANCE™ peel in

a series of 3 peel procedures in subjects with mild to moderate

facial photodamage, fine lines and fine wrinkling, and /or mild

superficial acne scarring. Study subjects had a series of 3 Obagi®

Blue Peel RADIANCE™ peel procedures, approximately 2 weeks

apart.

3 3

STUDY DESIGN

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

• Female or male subject, 21-45 years old, inclusive

• Have clinical diagnosis of mild to moderate facial photodamage,

fine lines and fine wrinkling, and/or mild superficial acne scarring

• Baseline Investigator Assessment Facial Overall Integrated

Photodamage Score 2-Mild or 3-Moderate

• Baseline Investigator Assessment Facial Overall Pigmentation

Intensity Scale 1-Minimal or 2-Mild

• Glogau Photodamage Classification Type I or Type II

• Fitzpatrick Skin Type II through light VI

4 4

MAIN INCLUSION CRITERIA

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

Home Use Study Products

AM PM

Nu-Derm® Gentle Cleanser

Nu-Derm® Sun Shield SPF 50

Nu-Derm® Gentle Cleanser

Subjects were provided with CLENZIderm™ Therapeutic Moisturizer and

instructed to use as needed for post-peel dryness, itching or redness.

STUDY TREATMENT REGIMEN

Obagi® Blue RADIANCE™ peel procedure done at Baseline Visit;

Day 14 Visit; Day 28 Visit (One layer Obagi® Blue RADIANCE™

per peel procedure.)

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 6

DEMOGRAPHICS

N 15

Gender Female (%) 86.7 (N=13)

Gender Male (%) 13.3 (N=2)

Age (Mean) 36

White/Caucasian (%) 86.7 (N=13)

Black/African American (%) 6.7 (N=1)

Asian (%) 6.7 (N=1)

Fitzpatrick Skin Type II (%) 46.7 (N=7)

Fitzpatrick Skin Type III(%) 26.7 (N=4)

Fitzpatrick Skin Type IV (%) 20.0 (N=3)

Fitzpatrick Skin Type VI (%) 6.7 (N=1)

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 7

DIAGNOSIS FOR PEEL

N 15

Photodamage (%) 53.3 (N=8)

Photodamage/ Acne Scarring (%)

13.3 (N=2)

Hyperpigmentation (%) 13.3 (N=2)

Acne Scarring/ Hyperpigmentation (%)

6.7 (N=1)

Tactile Roughness/ Dyspigmentation (%)

6.7 (N=1)

Sun Damage (%) 6.7 (N=1)

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

Investigator Assessments

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 9 9

Investigator Assessment of Photodamage

Score Overall Facial Photodamage

0 None

1 Minimal

2 Mild

3 Moderate

4 Severe

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 10 10

Investigator Assessment of

Pigmentation Intensity

Severity Score Overall Facial Pigmentation Intensity

None 0 No noticeable hyperpigmentation

Minimal 1 Localized deposits of pigment

Mild 2 Mild, diffuse deposits of pigment

Moderate 3 Moderate, diffuse deposits of pigment

Marked 4 Marked, dense deposits of pigment

Severe 5 Severe-dense deposits of pigment

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 11

STATISTICAL ANALYSIS GRAPHS

INVESTIGATOR ASSESSMENTS

BASELINE THROUGH WEEK 5 VISIT

11

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

7

13

7

27

6060

73

60

27

40

20

7

0

20

40

60

80

Screening Day 14 Day 28 Day 35

0 - None

1 - Minimal

2 - Mild

3 - Moderate

12 12

INVESTIGATOR ASSESSMENTS

FACIAL OVERALL INTEGRATED ASSESSMENT OF PHOTODAMAGE

BY VISIT

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

2.42.1

1.7

1.1

0.0

1.0

2.0

3.0

Screening Day 14 Day 28 Day 35

13

Mean Scores

Scale None (0) Minimal (1) Mild (2) Moderate (3)

INVESTIGATOR ASSESSMENTS

FACIAL OVERALL INTEGRATED ASSESSMENT OF PHOTODAMAGE

BY VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

27%

53%

80%

0%

20%

40%

60%

80%

100%

Day 14 Day 28 Day 35

Sub

ject

s (%

)

≥ 1 grade improvement

INVESTIGATOR ASSESSMENTS

FACIAL OVERALL INTEGRATED ASSESSMENT OF PHOTODAMAGE

(IMPROVEMENT FROM BASELINE)

14

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

7 7

20

27

33

47

60

53 53

40

2020

7 7

0

20

40

60

80

Screening Day 14 Day 28 Day 35

0 - None

1 - Minimal

2 - Mild

3 - Moderate

15 15

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – APPEARANCE OF

FINE LINES AND WRINKLES BY VISIT

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

1.91.6 1.5

1.0

0.0

1.0

2.0

3.0

Screening Day 14 Day 28 Day 35

16

Mean Scores

Scale None (0) Minimal (1) Mild (2) Moderate (3) Severe (4)

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – APPEARANCE OF

FINE LINES AND WRINKLES BY VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

33%40%

80%

0%

20%

40%

60%

80%

100%

Day 14 Day 28 Day 35

Sub

ject

s (%

)

≥ 1 grade improvement

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – APPEARANCE OF

FINE LINES AND WRINKLES BY VISIT

(IMPROVEMENT FROM BASELINE)

17

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

27

60

80

4047

33

20

47

20

713

7

0

20

40

60

80

100

Screening Day 14 Day 28 Day 35

0 - None

1 - Minimal

2 - Mild

3 - Moderate

18 18

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – TACTILE ROUGHNESS

BY VISIT

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

1.7

1.1

0.5

0.2

0.0

1.0

2.0

Screening Day 14 Day 28 Day 35

19

Mean Scores

Scale None (0) Minimal (1) Mild (2) Moderate (3) Severe (4)

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – TACTILE ROUGHNESS

BY VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

67%

0%

20%

40%

60%

80%

100%

Day 14 Day 28 Day 35

Sub

ject

s (%

)

≥ 1 grade improvement

20

INVESTIGATOR ASSESSMENTS

PHOTODAMAGE CHARACTERISTICS – TACTILE ROUGHNESS

BY VISIT

(IMPROVEMENT FROM BASELINE)

100% 100%

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

7

2013

93

8087

100

0

20

40

60

80

100

Baseline Day 14 Day 28 Day 35

0 - No

1 - Yes

21 21

INVESTIGATOR ASSESSMENTS

APPEARANCE OF FACIAL SKIN FIRMNESS /INCREASE FIRMNESS

CHANGE FROM BASELINE (ASSESSED FROM BASELINE PRE-PEEL PHOTO)

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

7

2727

40

53

60

73

60

40

13

0

20

40

60

80

Screening Day 14 Day 28 Day 35

0 - None

1 - Minimal

2 - Mild

22 22

INVESTIGATOR ASSESSMENTS

OVERALL FACIAL PIGMENTATION INTENSITY

BY VISIT

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

1.71.6

1.3

0.9

0.0

1.0

2.0

Screening Day 14 Day 28 Day 35

23

Mean Scores

Scale None (0) Minimal (1) Mild (2) Moderate (3) Severe (4)

INVESTIGATOR ASSESSMENTS

OVERALL FACIAL PIGMENTATION INTENSITY

BY VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

13%

40%

67%

0%

20%

40%

60%

80%

Day 14 Day 28 Day 35

Sub

ject

s (%

)

≥ 1 grade improvement

24

INVESTIGATOR ASSESSMENTS

OVERALL FACIAL PIGMENTATION INTENSITY

BY VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

100 100 100 100

0

20

40

60

80

100

Baseline (Peel #1) Day 14 (Peel #2) Day 28 ( Peel #3) Day 35 (Study Exit)

0 - No

1 - Yes

25 25

INVESTIGATOR ASSESSMENTS

SKIN APPEARS TIGHTER, SMOOTHER AND BRIGHTER LOOKING

CHANGE FROM BASELINE (ASSESSED FROM BASELINE PRE-PEEL PHOTO)

Percentage of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 26

TREATMENT RELATED

ADVERSE EVENTS

TOTAL # SUBJECTS

ADVERSE EVENT DESCRIPTION

AE INTENSITY

COMMENTS

1 Acne Flare Mild Acne flare stopped 11/10/12.

1 Worsening of Acne, Face

Mild Worsening of acne still ongoing 12/6/12.

No subjects discontinued due to treatment-related adverse events.

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 27

SUBJECT QUESTIONNAIRE RESPONSES

BASELINE, DAY 14, DAY 18 AND DAY 35 VISIT

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 28

SUBJECT QUESTIONNAIRE RESPONSES CURRENT SATISFACTION WITH SKIN FEATURES

BASELINE

(compared to Baseline pre-peel photo)

Percent (%) of Subjects

DAY 35

(compared to Baseline pre-peel photo)

Percent (%) of Subjects

Extremely

unsatisfied Unsatisfied Neutral Satisfied

Very

satisfied

Extremely

satisfied

Extremely

unsatisfied Unsatisfied Neutral Satisfied

Very

satisfied

Extremely

satisfied

– Appearance of fine

lines and wrinkles 6.7 53.3 26.7 6.7 6.7 13.3 26.7 26.7 33.3

– Smoothness of skin 40 40 13.3 6.7 6.7 40 53.3

– Firmness of skin 60 20 20 20 46.7 26.7 6.7

– Moisture level of skin 40 40 20 33.3 46.7 20

– Consistent skin tone

and coloration 26.7 46.7 20 6.7 6.7 20 53.3 20

– Appearance of brown

spots 40 53.3 6.7 26.7 40 26.7 6.7

– Pore size 20 40 40 6.7 33.3 40 20

– Glow/brightness of

skin 53.3 40 6.7 6.7 66.7 13.3 13.3

– Overall appearance

of skin 6.7 66.7 20 6.7 6.7 26.7 40 26.7

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 29

SUBJECT QUESTIONNAIRE RESPONSES SATISFACTION WITH PEEL PROCEDURE

DAY 14

(compared to Baseline pre-peel photo)

Percent (%) of Subjects

DAY 28

(compared to Baseline pre-peel photo)

Percent (%) of Subjects

Disagree

strongly

Disagree

Neutral

Agree

some

Agree

Agree

strongly

Disagree

strongly

Disagree

Neutral

Agree

some

Agree

Agree

strongly

I would continue to have this

facial peel procedure

performed.

6.7 46.7 46.7 6.7 6.7 33.3 53.3

I would recommend this facial

peel procedure to my friends. 13.3 13.3 33.3 40 20 13.3 40 26.7

The results of this facial peel

procedure were what I

expected.

6.7 20 33.3 26.7 13.3 13.3 6.7 20 46.7 13.3

The results of this facial peel

procedure were better than I

expected.

6.7 33.3 26.7 20 13.3 6.7 6.7 33.3 26.7 20 6.7

There was minimal downtime

after this facial peel procedure. 6.7 13.3 6.7 26.7 46.7 6.7 6.7 20 13.3 53.3

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 30

SUBJECT QUESTIONNAIRE RESPONSES SATISFACTION WITH PEEL PROCEDURE

DAY 35

(compared to Baseline pre-peel photo)

Percent (%) of Subjects

Disagree

strongly

Disagree

Neutral

Agree

some

Agree

Agree

strongly

I would continue to have this

facial peel procedure

performed.

26.7 6.7 26.7 40

I would recommend this facial

peel procedure to my friends. 13.3 13.3 33.3 40

The results of this facial peel

procedure were what I

expected.

13.3 26.7 46.7 13.3

The results of this facial peel

procedure were better than I

expected.

13.3 26.7 40 20

There was minimal downtime

after this facial peel procedure. 6.7 13.3 26.7 53.3

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 31

When did you first notice an improvement in

your skin’s appearance?

After the

1st Peel

After the

2nd Peel

After the

3rd Peel

I did not notice any

changes

40 46.7 6.7 6.7

Please rate your overall satisfaction

with the peel procedures you

received during this study.

Extremely

unsatisfied

Very

unsatisfied

Unsatisfied

Neutral

Satisfied

Very

satisfied

Extremely

satisfied

6.7 13.3 40 26.7 13.3

If you have received other facial aesthetic

treatments before this study, how would you

rate your results with this peel procedure

compared to previous facial treatments?

N/A

Much

worse

Worse

The same

Better

Much

better

60 13.3 20 6.7

SUBJECT QUESTIONNAIRE RESPONSES DAY 35

Percent (%) of Subjects

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

0

20

40

60

80

100

Subject ratings

of satisfied,

very satisfied,

or extremely

satisfied (%)

Appearance

of fine lines

and wrinkles

Firmness of

skin

Smoothness

of skin

60% 53% Very

Satisfied

Moisture

level of

skin

13% Good

7% Extremely Sat.

Satisfaction with Skin Features

at Day 35

32

93%

81%

67%

33% Very

Satisfied

27% Very

Satisfied 20% Very

Satisfied

27%

Satisfied

40%

Satisfied

47%

Satisfied 47%

Satisfied

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012

0

20

40

60

80

100

Subject ratings

of satisfied,

very satisfied,

or extremely

satisfied (%)

Consistent

skin tone &

coloration

Pore

size Appearance

of brown

spots

73%

20% Very

Satisfied

Overall

appearance

of skin

13% Extremely

Satisfied

Satisfaction with Skin Features

at Day 35

33

20% Very

Satisfied

53%

Satisfied

Glow/

brightness

of skin

7% Very Sat.

27%

Satisfied

40%

Satisfied

67%

Satisfied 40%

Satisfied

13% Very

Satisfied

27% Very

Satisfied

34%

60%

93%

67%

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 34

SAMPLE SUBJECT PHOTOGRAPHS

34

SUBJECT 001 KLJ

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 001 KLJ

SUBJECT 005 JKK

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 005 JKK

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 005 JKK

SUBJECT 006 APH

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 006 APH

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 006 APH

SUBJECT 007 JEK

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 007 JEK

OMP, INC. BLU001

SUZANNE BRUCE, MD

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 007 JEK

SUBJECT 009 YNC

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 009 YNC

SUBJECT 010 ALR

OMP, INC. BLU001

SUZANNE BRUCE, MD

2 WEEKS AFTER PEEL #2

BASELINE PRE-PEEL

SUBJECT 010 ALR

OMP, INC. BLU001

SUZANNE BRUCE, MD

2 WEEKS AFTER PEEL #2

BASELINE PRE-PEEL

BASELINE PRE-PEEL

SUBJECT 010 ALR

2 WEEKS AFTER PEEL #2

SUBJECT 012 JAE

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 012 JAE

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 012 JAE

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 014 S-H

OMP, INC. BLU001

SUZANNE BRUCE, MD

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

BASELINE PRE-PEEL

SUBJECT 014 S-H

OMP, INC. BLU001

SUZANNE BRUCE, MD

BASELINE PRE-PEEL

1 WEEK AFTER PEEL #3

(35 DAYS FROM BASELINE)

SUBJECT 014 S-H

BLU-001 Blue Peel RADIANCE™

CONFIDENTIAL INTERNAL OMP CORPORATE USE ONLY - NOT FOR DISTRIBUTION

OMPI DECEMBER 2012 57

CONCLUSIONS • 100% subjects had tighter, smoother, brighter looking skin after peel #1

• 100% subjects had minimal or no tactile roughness after series 3 peels

• 100% subjects had at least 1 grade improvement tactile roughness after peel #2

• 93% subjects had firmer appearing skin after peel #1

• 80% subjects had at least 1 grade improvement in appearance of fine

lines and wrinkles after series 3 peels

• 67% subjects had at least 1 grade improvement in pigmentation intensity after series 3 peels

• 80% subjects at least satisfied with series of 3 peels

• Most visible improvement seen in photo images after peel #3

Recommended